Overview of Clinical Trial phases

Phase I study – an initial safety trial to determine dosages, involving a small group of adult participants.  This is a small-scale trial to assess whether the vaccine is safe in humans and what immune response it evokes.  Phase Ia will trial the vaccine in healthy adults in the UK, and Phase Ib will test the vaccine in a more ‘relevant’ target population.  For vaccines for infectious outbreak diseases, this will be a country where an outbreak is likely to occur.

Phase II study – a trial to look at safety and immune response (immunogenicity), in a larger group of participants.  This group is usually the target group, for whom the vaccine is intended, for e.g. adults, children, and/or infants. The trial will be designed to generate data on the safety and efficacy of the vaccine (the percentage reduction of disease in a vaccinated group of people compared to an unvaccinated group) against artificial infection and clinical disease.

Phase III study – a larger-scale trial on whether the vaccine induces a level of immunity that would prevent disease and provides evidence that the vaccine can reduce disease cases in a given population.  This is done in a larger group (many hundreds of trial participants) in order to gain statistically significant safety and efficacy data for the SPC (Summary of Product Characteristics), and may entail conducting trials at several sites to evaluate efficacy under natural disease conditions.  If the vaccine shows safety and efficacy over a defined period, the manufacturer can apply to the relevant regulatory authorities to licence the product.

Phase IV - also called post-marketing surveillance, after the vaccine has been licensed and introduced into use, this stage collects data across wide ranging populations that are using the vaccine, in order to detect rare adverse effects and assess long term efficacy.

Support for designing, setting up and running a vaccine clinical trial:
There are many steps involved in running a vaccine clinical trial, with legal and good practice arrangements surrounding setting up and managing a Clinical Trial of an Investigational Medicinal Product (CTIMP).

The Clinical Trials Toolkit was initially developed and launched in 2004 by the MRC and the Department of Health to help clinical trialists and R&D managers understand the regulations and requirements for conducting trials. As the lead organisation for funding clinical trials, the tool is now managed by NIHR.

The Clinical Trials Toolkit is an interactive colour-coded routemap to help navigate through the legal and good practice requirements, and indicates which aspects of these are relevant to wider clinical research in general. It includes an overview of trial practices, along with more detailed information available at ‘stations’ along the route.

Clinical trials - general